Structural Basis for Potent Cross-Neutralizing Human Monoclonal Antibody Protection against Lethal Human and Zoonotic Severe Acute Respiratory Syndrome Coronavirus Challenge

By B. Rockx, D. Corti, Eric F. Donaldson, T. Sheahan, K. Stadler, A. Lanzavecchia, Ralph S. Baric. 2008

144 citations recorded by the source corpus.

Subfields: Animal Science and Zoology, Epidemiology, Infectious Diseases

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Animal Science and Zoology

In Epidemiology

In Infectious Diseases

Citations in the corpus

Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2 (2020, positive): “We previously characterized potent human neutralizing Abs from rare memory B cells of individuals infectedwith SARS-CoV (Rockx et al., 2008; Traggiai et al., 2004) or Middle East respiratory syndrome (MERS)-CoV (Corti et al.”
Structural insights into coronavirus entry (2019, result): “Specifically, SARS-CoV and MERS-CoV S structures in complex with neutralizing antibodies isolated from survivors showed both antibodies competitively blocked receptor interaction, in agreement with previous surface plasmon resonance data (Corti et al., 2015; Rockx et al., 2008; Traggiai et al., 2004”
Protocol and Reagents for Pseudotyping Lentiviral Particles with SARS-CoV-2 Spike Protein for Neutralization Assays (2020, background): “Indeed, for other coronaviruses, neutralizing antibodies are protective in mouse models of infection [16–20] and associated with at least some reduced susceptibility to re-infection or disease in humans [15,21,22].”
From SARS to MERS, Thrusting Coronaviruses into the Spotlight (2019, background): “Another strategy used human immunoglobulin transgenic mice immunized with full-length SARS-CoV S proteins [125] [126] [127] .”
A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures (2020, background): “…the function of some human monoclonal antibodies or vaccines in mice, this phenotype was not observed with mouse-adapted strains of SARS-CoV 40–42 and the mutations did not alter the potent neutralizing activity of two human monoclonal antibodies that target the SARS-CoV-2 S-protein RBD 43 .”
Recombination, Reservoirs, and the Modular Spike: Mechanisms of Coronavirus Cross-Species Transmission (2009, background): “Multiple studies have demonstrated the cross-neutralizing potential of human monoclonal antibodies (neutralizing MAbs [nMAbs]) raised against the SARS-CoV Spike and that the vast majority of these epitopes map to the RBD (10, 47, 114, 123, 127, 162).”
Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein (2020, background): “We note that most SARS-CoV neutralizing Abs isolated to date target the S domain and that several of them recognize the RBM and prevent receptor engagement (Hwang et al., 2006; Rockx et al., 2008; Rockx et al., 2010; Traggiai et al., 2004; Walls et al., 2019).”
Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies (2020, unknown): “The RBD-binding Fab(s) from COV21 plasma resembled binding of S230, a VH3-30 mAb isolated from a SARS-CoV patient that blocks ACE2 receptor binding (Rockx et al., 2008).”
Unexpected Receptor Functional Mimicry Elucidates Activation of Coronavirus Fusion (2020, unknown): “Structure of the SARS-CoV S Glycoprotein in Complex with the Human S230 Antibody The S230 antibody was isolated frommemory B cells of a SARSCoV-infected individual and potently neutralized a broad spectrum of SARS-CoV isolates of human and animal origin (Rockx et al., 2008; Traggiai et al., 2004).”
Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual (2020, background): “Moreover, the neutralizing potency correlated with the degree of S-ACE2 inhibition (Rockx et al., 2008).”
A mouse-adapted SARS-CoV-2 model for the evaluation of COVID-19 medical countermeasures (2020, methodology): “Coupling predictive molecular modeling and reverse genetics 21 Although the SARS-CoV-2 MA RBD mutations may attenuate the function of select human monoclonal antibodies or vaccines in mice, this phenotype was not observed with mouse adapted strains of SARS-CoV-1 [29] [30] [31] .”